Key Findings
- Zhong et al. included eight randomized trials and 587 participants with nonalcoholic fatty liver disease. [1]
- Across the pooled interventions, ALT was lower by 9.16 U/L (95% CI −16.24 to −2.08) and AST by 6.57 U/L (95% CI −10.03 to −3.12) compared with control. [1]
- The silymarin-alone subgroup had smaller estimates: ALT −5.08 U/L and AST −5.44 U/L. Results from combination interventions should not be attributed entirely to silymarin. [1]
- Liver-enzyme changes are surrogate markers. This review does not establish that silymarin prevents liver failure, reverses fibrosis or produces the previously stated 52% steatosis response. [1]
- NCCIH describes liver-disease results as conflicting or too limited for conclusions; two NCCIH-funded trials did not show benefit. [4]